Autoimmune Diseases
Roche and COUR Pharmaceuticals Collaborate on Autoimmune Disease Treatment in Deal Worth Over $900 Million
Roche, COUR Pharmaceuticals, autoimmune disease, Genentech, antigen-specific immune tolerance platform, biotech collaboration
BMS’ CAR-T Therapy Shows Promising Results in Treating Lupus, Achieving Sustained Responses in Phase 1 Trial
CAR T therapy, Lupus treatment, Bristol Myers Squibb (BMS), Systemic lupus erythematosus (SLE), Autoimmune diseases, Cell therapy, Clinical trials
Nkarta Shifts Focus to Autoimmune Diseases, Deprioritizing Cancer Programs
Nkarta, autoimmune diseases, CAR NK cell therapy, NKX019, lupus nephritis, cancer programs, deprioritization
Jade Biosciences and Aerovate Therapeutics Announce Strategic Merger to Advance Autoimmune Disease Therapies
Reverse merger, Jade Biosciences, Aerovate Therapeutics, Paragon Therapeutics, Autoimmune diseases, JADE-001, IgA nephropathy (IgAN), Biotechnology
GSK Expands Lupus Portfolio with $300M Upfront Deal for T-Cell Engager
GSK, lupus, T-cell engager, Chimagen Biosciences, autoimmune diseases, pharmaceutical deals
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration
Lyell Immunopharma Acquires ImmPACT Bio to Bolster CAR T-cell Therapy Pipeline
Lyell Immunopharma, ImmPACT Bio, CAR T-cell therapy, pipeline acquisition, biotechnology, cancer treatment, autoimmune diseases
Otsuka Seeks Accelerated Approval for Sibeprenlimab in IgA Nephropathy Following Positive Phase III Interim Results
Otsuka, sibeprenlimab, IgA nephropathy, Phase III trial, accelerated approval, FDA, kidney disease, autoimmune disease, APRIL antibody.
IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce
IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644
IGM Biosciences Shifts Focus to Autoimmune Diseases Amid Leadership Changes
IGM Biosciences, autoimmune diseases, C-suite exits, biotechnology, immunology, arthritis, lupus